Author: Ria Lassaunière; Anders Frische; Zitta B Harboe; Alex CY Nielsen; Anders Fomsgaard; Karen A Krogfelt; Charlotte S Jørgensen
Title: Evaluation of nine commercial SARS-CoV-2 immunoassays Document date: 2020_4_10
ID: 8cg5yj20_27
Snippet: The differences observed for the sensitivity and specificity of the SARS-CoV-2-specific total antibody testing and antibody type ELISAs correspond to previous reports. . This notably lower sensitivity for SARS-CoV-2-specific IgG detection is in agreement to that observed here for the Euroimmun IgG ELISA (65%). In the present study the Wantai IgG and Euroimmun IgG ELISAs could not be compared due to unavailability of the former. The possibility th.....
Document: The differences observed for the sensitivity and specificity of the SARS-CoV-2-specific total antibody testing and antibody type ELISAs correspond to previous reports. . This notably lower sensitivity for SARS-CoV-2-specific IgG detection is in agreement to that observed here for the Euroimmun IgG ELISA (65%). In the present study the Wantai IgG and Euroimmun IgG ELISAs could not be compared due to unavailability of the former. The possibility that overall lower sensitivity of SARS-CoV-2 IgG ELISAs may be a more universal occurrence rather than manufacturer dependent warrants further investigation. In addition to lower sensitivities, the Euroimmun IgA and IgG ELISAs are also more prone to cross-react with negative sera as described in the present study and in a separate analysis of the beta-versions of these assays [10].
Search related documents:
Co phrase search for related documents- antibody testing and IgG detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- antibody testing and IgG elisa: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- antibody testing and low sensitivity: 1, 2, 3, 4, 5
- antibody testing and negative sera: 1, 2, 3, 4, 5, 6, 7
- antibody testing and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antibody testing and previous report: 1, 2
- antibody testing and SARS IgG detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- antibody testing and SARS IgG elisa: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- antibody testing and specificity sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antibody type and Euroimmun IgG elisa: 1
- antibody type and IgG detection: 1, 2
- antibody type and IgG elisa: 1, 2, 3, 4, 5, 6
- antibody type and negative sera: 1
- antibody type and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antibody type and SARS IgG elisa: 1
- antibody type and specificity sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- assay version and low sensitivity: 1
- assay version and specificity sensitivity: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date